Amount of suitable people: CDEC discussed the uncertainty in the number of patients with reasonably intense to severe hemophilia B in Canada suitable for etranacogene dezaparvovec. Scientific industry experts consulted by CADTH indicated that some people that are labeled as acquiring delicate or moderate illness may have a intense bleeding phenotyp